Return to previous page|
Southern Hemisphere 2010 1
Candidate influenza vaccine viruses
NIBSC code
H1N1 2, 3
A/California/7/2009 wild type virus 4
09/104
NYMC X-179A reassortant derived from A/California/7/2009
09/124
NYMC X-181 reassortant derived from A/California/7/2009
09/176
NYMC X-181A reassortant derived from A/California/7/2009
09/178
IVR-153 reassortant derived from A/California/7/2009
09/144
NIBRG-121 reassortant derived from A/California/7/2009
09/122
NIBRG-121xp reassortant derived from A/California/7/2009
09/166
NIBRG-122 reassortant derived from A/California/7/2009
09/130
H3N2
A/Perth/16/2009 wild type virus
09/202 available w/c 28 th September
B
B/Brisbane/60/2008
08/276
B/Brisbane/33/2008
08/280 or 08/298
NYMC BX-31 reassortant derived from B/Brisbane/60/2008
08/360
NIB-58 reassortant derived from B/Brisbane/60/2008
08/364
1 Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season
2 For further information on the candidate (H1N1)v vaccine viruses
3 Currently in use for pandemic (H1N1)v vaccine manufacture
4 Wild type (H1N1)v virus should be handled according to WHO recommendations
(see below for pricing information)
H1N1
A/Brisbane/59/2007
07/346
IVR-148 reassortant derived from A/Brisbane/59/2007
07/344
A/Brisbane/10/2007 wild type virus
07/250
A/Uruguay/716/2007 wild type virus-
07/354
NIB-50 reassortant derived from A/Uruguay/716/2007
07/358
IVR-149 reassortant derived from A/Uruguay/716/2007
07/362
NYMC X-175C reassortant derived from A/Uruguay/716/2007
07/360
1WHO recommended composition of influenza virus vaccines for use in the 2009/2010 northern hemisphere influenza season: http://www.who.int/csr/disease/influenza/recommendations2009_10north/en/index.html
Reagents for influenza vaccine standardisation
A/Brisbane/59/2007 IVR-148 antigen
08/100
A/Brisbane/59/2007 IVR-148 antiserum
08/112
A/Brisbane/10/2007-like antigen (NYMC X-175C derived from A/Uruguay/716/2007)
08/278
A/Brisbane/10/2007-like antiserum (NYMC X-175C derived from A/Uruguay/716/2007)
08/246
B/Brisbane/60/2008 like antigen
08/352
B/Brisbane/60/2008 like antiserum
08/354
Neuraminidase reagents
N1
antiserum prepared from A/New Caledonia/20/99
04/230
N2
antiserum prepared from A/Wyoming/3/2003
04/258
NA antiserum prepared from B/Jiangsu/10/2003
04/228
NA antiserum prepared from B/Malaysia/2506/2004
05/252
NA antiserum prepared for B/Florida/4/2006 under development
To be confirmed
Pricing information
Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £60 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £60 handling fee.
Your browser does not support JavaScript!